



Vivacta Closes £4 million Financing

*To maximise potential of breakthrough technology platform
in developing Point of Care diagnostics*

Sittingbourne, Kent, UK, 10th November 2010 -- Vivacta Limited, the medical diagnostics company with a revolutionary platform for point of care testing, announces the close of a £4 million financing round. The current shareholders, HBM BioVentures, IDInvest Partners (formerly AGF Private Equity), Spark Ventures and Viking, all participated in the round.

Vivacta's innovative piezofilm technology platform enables the development of a new generation of near-patient diagnostic products achieving very high sensitivity and wide dynamic range, equivalent to laboratory testing. The test utilises whole blood samples and requires only a finger prick sample, providing actionable results within 10 minutes.

Vivacta has successfully developed a diagnostic test for thyroid stimulating hormone (TSH), one of the most widely prescribed laboratory tests and the industry gold standard for immunoassays by which major diagnostic companies measure the performance of competing platforms. Vivacta's TSH product demonstrates the high sensitivity, wide dynamic range, precision and speed to result enabled by the technology. Vivacta is also developing a multiple analyte cardiovascular diagnostic test for use in the emergency room and acute care settings, where there is a compelling need for rapid diagnosis of possible heart attack and related time-critical medical conditions.

Dr Tim Carter, Chief Executive Officer of Vivacta and co-inventor of the piezofilm platform technology, said: "Our technology has the potential to revolutionise point of care diagnosis. This fundraising enables us to continue to maximise the potential of our platform and demonstrates the commitment of our investors in the Company."

Vivacta's technology has been used to measure both small and large molecules and the goal ultimately is to measure nucleic acids. Target applications include diagnosis of infections, sepsis and stroke, companion diagnostics, therapeutic drug monitoring, vaccination status and therapeutic effectiveness monitoring such as the detection of anti-drug antibodies, as well as personalised medicine applications.

Vivacta collaborates with healthcare companies to develop point of care diagnostics for these applications.

Vivacta's patented system is simple to use, cost effective, and is packaged within a small, self contained cartridge with all reagents dried down. The unique cartridge system reduces the amount of patient blood required and removes the need for red cell separation. Single and multiple assay cartridges and readers have been developed. The multiple assay system allows simultaneous testing of several different analytes or the same analyte more than once to further enhance dynamic range and sensitivity.

Cartridges are inserted by the user into a compact reader which provides data rapidly to users at the point of care and simultaneously to remote locations such as laboratories within

decentralised healthcare networks. The system is designed to meet the criteria for CLIA waiver.

Vivacta has a proven product development and manufacturing process with a certified quality system. Its pilot facility for manufacturing cartridges provides partners with small-scale manufacture and process development resource. Vivacta has established a strong, independent IP base with a portfolio comprising over 10 patent families.

-ends-

About Vivacta

Vivacta Limited is applying its expertise in piezofilm technology to develop a range of new generation high performance Point of Care (POC) diagnostics able to deliver quantitative readings within 10 minutes from a single pin prick of blood.

The Company's platform technology exploits the piezoelectric effect by which thermal perturbations on a piezofilm surface cause an electric charge to be produced. The measurement of this electric charge enables monitoring of chemical activity – or rate of binding between antibody and analyte – in an assay. In harnessing this piezofilm platform technology, Vivacta has developed PoC diagnostic products able to produce and present sensitive, precise and fully quantitative results, equivalent to those produced in laboratories.

Vivacta has generated an independent intellectual property position of over 10 patent families protecting the use of piezofilms in diagnostic assays. Vivacta's investors include HBM BioVentures, IDInvest (formerly AGF), Spark Ventures and Viking. For more information please visit www.vivacta.com

Contacts:

Vivacta

Oliver Boucher

Tel: +44 1795 419400

ob@vivacta.com

Capital MS&L

Mary Clark, Justine Lamond & Hollie Vile

Tel: +44 (0)20 7307 5337

vivacta@capitalmsl.com